Literature DB >> 21368239

Suppression of cytochrome P450 reductase (POR) expression in hepatoma cells replicates the hepatic lipidosis observed in hepatic POR-null mice.

Todd D Porter1, Subhashis Banerjee, Elzbieta I Stolarczyk, Ling Zou.   

Abstract

Cytochrome P450 reductase (POR) is a microsomal electron transport protein essential to cytochrome P450-mediated drug metabolism and sterol and bile acid synthesis. The conditional deletion of hepatic POR gene expression in mice results in a marked decrease in plasma cholesterol levels counterbalanced by the accumulation of triglycerides in lipid droplets in hepatocytes. To evaluate the role of cholesterol and bile acid synthesis in this hepatic lipidosis, as well as the possible role of lipid transport from peripheral tissues, we developed a stable, small interfering RNA (siRNA)-mediated cell culture model for the suppression of POR. POR mRNA and protein expression were decreased by greater than 50% in McArdle-RH7777 rat hepatoma cells 10 days after transfection with a POR-siRNA expression plasmid, and POR expression was nearly completely extinguished by day 20. Immunofluorescent analysis revealed a marked accumulation of lipid droplets in cells by day 15, accompanied by a nearly 2-fold increase in cellular triglyceride content, replicating the lipidosis seen in hepatic POR-null mouse liver. In contrast, suppression of CYP51A1 (lanosterol demethylase) did not result in lipid accumulation, indicating that loss of cholesterol synthesis is not the basis for this lipidosis. Indeed, addition of cholesterol to the medium appeared to augment the lipidosis in POR-suppressed cells, whereas removal of lipids from the medium reversed the lipidosis. Oxysterols did not accumulate in POR-suppressed cells, discounting a role for liver X receptor in stimulating triglyceride synthesis, but addition of chenodeoxycholate significantly repressed lipid accumulation, suggesting that the absence of bile acids and loss of farnesoid X receptor stimulation lead to excessive triglyceride synthesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21368239      PMCID: PMC3100902          DOI: 10.1124/dmd.111.038562

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  23 in total

1.  Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (POR) null mice.

Authors:  Xiu Jun Wang; Mark Chamberlain; Olga Vassieva; Colin J Henderson; C Roland Wolf
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

2.  Hepatic gene expression changes in mouse models with liver-specific deletion or global suppression of the NADPH-cytochrome P450 reductase gene. Mechanistic implications for the regulation of microsomal cytochrome P450 and the fatty liver phenotype.

Authors:  Yan Weng; Concetta C DiRusso; Andrew A Reilly; Paul N Black; Xinxin Ding
Journal:  J Biol Chem       Date:  2005-07-08       Impact factor: 5.157

3.  Hepatic cytochrome P450 reductase-null mice reveal a second microsomal reductase for squalene monooxygenase.

Authors:  Li Li; Todd D Porter
Journal:  Arch Biochem Biophys       Date:  2007-03-02       Impact factor: 4.013

4.  A comparison of delipidated sera used in studies of sterol synthesis by human mononuclear leukocytes.

Authors:  H R Slater; F W Robertson
Journal:  J Lipid Res       Date:  1979-03       Impact factor: 5.922

5.  Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic Acid homeostasis.

Authors:  Diana M E Otto; Colin J Henderson; Dianne Carrie; Megan Davey; Thomas E Gundersen; Rune Blomhoff; Ralf H Adams; Cheryll Tickle; C Roland Wolf
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

6.  Inhibition of sterol 4alpha-methyl oxidase is the principal mechanism by which garlic decreases cholesterol synthesis.

Authors:  Dev K Singh; Todd D Porter
Journal:  J Nutr       Date:  2006-03       Impact factor: 4.798

7.  The disruption of hepatic cytochrome p450 reductase alters mouse lipid metabolism.

Authors:  David M Mutch; Bernward Klocke; Peter Morrison; Carol A Murray; Colin J Henderson; Martin Seifert; Gary Williamson
Journal:  J Proteome Res       Date:  2007-08-28       Impact factor: 4.466

8.  Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase.

Authors:  Jun Gu; Yan Weng; Qing-Yu Zhang; Huadong Cui; Melissa Behr; Lin Wu; Weizhu Yang; Li Zhang; Xinxin Ding
Journal:  J Biol Chem       Date:  2003-04-15       Impact factor: 5.157

Review 9.  LXRS and FXR: the yin and yang of cholesterol and fat metabolism.

Authors:  Nada Y Kalaany; David J Mangelsdorf
Journal:  Annu Rev Physiol       Date:  2006       Impact factor: 19.318

10.  Increased gap junction assembly between cultured cells upon cholesterol supplementation.

Authors:  R Meyer; B Malewicz; W J Baumann; R G Johnson
Journal:  J Cell Sci       Date:  1990-06       Impact factor: 5.285

View more
  8 in total

1.  7-Dehydrocholesterol reductase activity is independent of cytochrome P450 reductase.

Authors:  Ling Zou; Li Li; Todd D Porter
Journal:  J Steroid Biochem Mol Biol       Date:  2011-07-05       Impact factor: 4.292

2.  Dysregulation of Npas2 leads to altered metabolic pathways in a murine knockout model.

Authors:  Derek O'Neil; Hector Mendez-Figueroa; Toni-Ann Mistretta; Chunliu Su; Robert H Lane; Kjersti M Aagaard
Journal:  Mol Genet Metab       Date:  2013-09-05       Impact factor: 4.797

3.  A Luciferase-fragment Complementation Assay to Detect Lipid Droplet-associated Protein-Protein Interactions.

Authors:  Petra Kolkhof; Michael Werthebach; Anna van de Venn; Gereon Poschmann; Lili Chen; Michael Welte; Kai Stühler; Mathias Beller
Journal:  Mol Cell Proteomics       Date:  2016-12-12       Impact factor: 5.911

Review 4.  Electron Transfer Pathways in Cholesterol Synthesis.

Authors:  Todd D Porter
Journal:  Lipids       Date:  2015-09-07       Impact factor: 1.880

5.  NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology.

Authors:  David S Riddick; Xinxin Ding; C Roland Wolf; Todd D Porter; Amit V Pandey; Qing-Yu Zhang; Jun Gu; Robert D Finn; Sebastien Ronseaux; Lesley A McLaughlin; Colin J Henderson; Ling Zou; Christa E Flück
Journal:  Drug Metab Dispos       Date:  2012-10-19       Impact factor: 3.922

Review 6.  Pharmacogenomics of human P450 oxidoreductase.

Authors:  Amit V Pandey; Patrick Sproll
Journal:  Front Pharmacol       Date:  2014-05-09       Impact factor: 5.810

7.  Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells.

Authors:  Tamara Heintze; Kathrin Klein; Ute Hofmann; Ulrich M Zanger
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

8.  H-rev107 Regulates Cytochrome P450 Reductase Activity and Increases Lipid Accumulation.

Authors:  Fu-Ming Tsai; Mao-Liang Chen; Lu-Kai Wang; Ming-Cheng Lee
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.